BPC-157

Pentadecapeptide studied for tissue repair and gut-protective effects.

Products

BPC-157: Mechanism, Preclinical Evidence & Research Use (2026)

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice. It is one of the most studied tissue-repair peptides in preclinical science, with a large body of rodent data from the Sikiric group at the University of Zagreb covering tendon, ligament, gut, and neuro-protective models [1][7][8].

By the end of this page you will understand what BPC-157 is, what the preclinical science shows, and how it compares to related peptides.

Key Facts About BPC-157

  • 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV), also known as bepecin / PL 14736.
  • Extensive rodent preclinical data spanning gut protection, tendon repair, ligament healing, anti-inflammation, and neuroprotection [1][7][8].
  • Proposed mechanisms: VEGFR-2 angiogenic signalling, nitric oxide upregulation, FAK–paxillin cell-migration pathway [7][8][9][10].
  • Supplied for research use only; no marketing authorisation for human use as of 2026.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15 amino acids, sequence GEPPPGKPADDAGLV) derived from a fragment of a larger "Body Protection Compound" protein identified in human gastric juice, synthesised in laboratories for research purposes [1]. Its full name is Body Protection Compound 157. Literature also references it as bepecin and the development code PL 14736 [1].

The parent BPC protein occurs naturally in gastric secretions, but the 15-residue BPC-157 fragment itself is chemically synthesised — typically by solid-phase peptide synthesis — giving researchers a stable, reproducible compound that retains the cytoprotective activity of the parent molecule whilst showing unusual stability in gastric juice compared with most short peptides [1].

Mechanistic work focuses on VEGFR-2 receptor binding and related growth-factor signalling. BPC-157 is frequently studied alongside TB-500 in injury-recovery research contexts, though the two have distinct origins and proposed mechanisms.

How BPC-157 Works: The Proposed Mechanisms

BPC-157's proposed mechanisms centre on growth-factor signalling, nitric oxide modulation, and cytoskeletal pathways that govern cell migration — all characterised in rodent and in-vitro models [1][7].

VEGFR-2 and angiogenic signalling

The most-cited mechanistic claim is that BPC-157 engages VEGFR-2 (the vascular endothelial growth factor receptor type 2), promoting new blood-vessel formation at injury sites. Rodent data show BPC-157 increases angiogenesis and reduces inflammatory damage in tendon, ligament, and gut tissue, with the VEGFR-2 axis proposed as the upstream trigger [7]. EGF receptor signalling has also been invoked as a parallel pathway implicated in epithelial repair [7].

Nitric oxide and the FAK–paxillin pathway

Preclinical work attributes part of BPC-157's cytoprotective effect to upregulation of nitric oxide (NO) synthesis, which improves mucosal blood flow and may explain the gastric and vascular findings in rodent models [7][8].

A separate mechanistic strand implicates the FAK–paxillin pathway, a focal-adhesion signalling cascade that controls fibroblast and tenocyte migration. Activation of this pathway has been proposed to underlie the accelerated tendon regeneration seen in rat Achilles transection studies, because cell migration is essential for tissue remodelling [9][10].

BPC-157 Evidence Table: Preclinical Data Overview (2026)

The evidence base for BPC-157 is robust at the preclinical level — extensive rodent studies, multiple tissue systems, clear mechanistic hypotheses — making it one of the most-researched unlicensed peptides available. Human trials remain an active area to watch. Registry checks on ClinicalTrials.gov and ISRCTN on 12 February 2026 showed no large pivotal trials with published outcomes as of that date [3].

Evidence Review Methodology

Each claimed benefit is graded against:

  1. Presence of replicated animal-model data from at least one peer-reviewed source.
  2. Presence of a registered, completed human trial with published outcomes on PubMed or ClinicalTrials.gov.
  3. Independent replication outside the Sikiric group at the University of Zagreb, which authored the bulk of the foundational rodent work [1][10].

The table

Claimed BenefitAnimal-Model EvidenceHuman Clinical EvidenceEvidence Tier
Gastrointestinal protection (gastric ulcers, colitis, NSAID-induced damage)Sikiric group rodent studies, 1990s–2010s: accelerated healing of gastric ulcers, colitis and ischaemia/reperfusion injury at doses around 10 µg/kg IP [1][10]. Large and consistent dataset.Registered trials ongoing; no large published RCT outcomes as of 2026 [3].Preclinical
Tendon and ligament repair2010 rat Achilles tendon transection study: stronger tendons, better-organised collagen, earlier functional recovery vs. controls [1][3]. Additional rodent MCL, quadriceps and knee-ligament studies [1].No large published RCT outcomes as of 2026 [7].Preclinical
Anti-inflammatory effectsRodent data: reduced inflammatory damage in gut and musculoskeletal injury models; VEGFR-2-linked angiogenesis and NO upregulation proposed [1][7].No large published RCT outcomes as of 2026 [3].Preclinical
Bone healingRodent fracture and segmental-defect work cited within Sikiric-group reviews [1].No large published RCT outcomes as of 2026 [2].Preclinical
Neuroprotection (TBI, stroke, neuropathy models)Rodent models: reduced lesion volume and improved functional scores [1][7].No large published RCT outcomes as of 2026 [3].Preclinical

BPC-157 Benefits: What the Preclinical Research Shows

Gut Protection

BPC-157 has been most extensively studied for gastrointestinal cytoprotection. Sikiric-group experiments from the 1990s through 2010s reported that intraperitoneal or oral BPC-157 (around 10 µg/kg) reduced gastric lesion size from ethanol, NSAID, and stress-induced injury. The peptide also improved mucosal blood flow and accelerated healing in colitis and intestinal ischaemia/reperfusion models [1][7]. A 2018 Sikiric review consolidated these findings across a large series of rodent protocols [7].

Tendon and Ligament Repair

The most-cited tendon evidence is the 2010 rat Achilles tendon transection study from the Sikiric group. BPC-157-treated rats showed stronger tendons, better-organised collagen fibres, and earlier functional recovery than controls [1]. Follow-up rat work from the same group reported improved healing of ruptured medial collateral ligaments, transected quadriceps, and damaged knee ligaments, with enhanced angiogenesis cited as the proposed mechanism [1][7].

Researchers frequently study BPC-157 alongside TB-500 in musculoskeletal recovery contexts.

Anti-Inflammatory Effects

In rodent models, BPC-157 has been associated with reduced inflammatory damage in both gut and musculoskeletal injury contexts. Proposed mechanisms involve VEGFR-2-linked angiogenesis and nitric oxide upregulation [1][7].

Regulatory status

BPC-157 is an investigational research compound supplied strictly for laboratory research use only. It is not an approved medicine, and its regulatory status differs between countries. Verify the applicable rules in your own jurisdiction before handling.

BPC-157 and TB-500: The 'Wolverine Stack' in Research

The "Wolverine Stack" is the informal name for combining BPC-157 with TB-500, a synthetic fragment of Thymosin Beta-4. Both are among the most-studied unlicensed research peptides in the musculoskeletal recovery literature.

TB-500 is derived from Thymosin Beta-4, a naturally occurring protein involved in actin regulation, angiogenesis, and cell migration [2][5]. The two peptides target overlapping but distinct mechanistic pathways, which is why researchers frequently study them in combination protocols.

How BPC-157 Compares to Other Research Peptides

BPC-157 is one of the most data-rich unlicensed research peptides available, with decades of rodent studies across multiple tissue systems. It sits in a different regulatory category to GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which carry licensed human indications backed by large Phase III RCTs [4].

Other tissue-repair peptides

TB-500 is the most popular BPC-157 companion peptide for musculoskeletal research. GHK-Cu, a copper-binding tripeptide, is another research-grade option.

Frequently Asked Questions About BPC-157

What is BPC-157 used for in research?

In preclinical research, BPC-157 is used to study accelerated healing of gastric ulcers, colitis, Achilles tendon transections, ligament ruptures, and muscle injury in rodent models. The primary research group is the Sikiric team at the University of Zagreb [1][7].

What are the known side effects of BPC-157?

In rodent studies, BPC-157 has generally been reported as well-tolerated at microgram-per- kilogram doses, with no consistent organ toxicity in short-term protocols [1][7]. Anecdotal reports from research communities include injection-site irritation, mild nausea, and headaches — none drawn from formal pharmacovigilance data. Long-term human safety data are not available as of 2026 [3].

How does BPC-157 differ from TB-500?

BPC-157 is a 15-amino-acid synthetic fragment derived from a human gastric juice protein [1]. TB-500 is a synthetic fragment of thymosin beta-4. The two peptides have distinct origins and proposed mechanisms but are frequently studied together in musculoskeletal recovery research.

Supplied for research use only. Not for human consumption.

Written by

Ian Wilson

Principal Investigator, Joint Center for Structural Genomics

Ian Wilson, DPhil, FRS is the Hansen Professor of Structural Biology at The Scripps Research Institute and the Principal Investigator of the JCSG. Trained at Oxford and Harvard, he is internationally recognised for his X-ray crystallographic studies of influenza haemagglutinin, HIV envelope glycoproteins, T-cell receptors and broadly neutralising antibodies. He has authored more than 600 publications and served as President of the American Crystallographic Association.